Attrition Intelligence
adaptivePRO is an end-to-end operational intelligence platform that combines wearable integration and AI-driven analytics to identify early attrition risk in clinical trials.
Participant dropout in clinical trials is rarely sudden. It follows a period of disengagement that conventional monitoring is not designed to detect.
adaptivePRO was built to close that gap — surfacing actionable intelligence at the point where retention outcomes can still be influenced.
adaptivePRO is an end-to-end operational intelligence platform that combines wearable integration and AI-driven analytics to dynamically identify early attrition risk in clinical trials.
Operationally
unobtrusive.
Contextually
precise.
Timed for
intervention.
We are working with a small number of early partners. If participant retention is a persistent challenge in your trials, we would love to connect with you.
In 1846, French astronomer and mathematician Urbain Le Verrier noticed that Uranus was not where Newtonian mechanics said it should be. Rather than attributing the discrepancy to measurement error, he proposed that an unobserved planet was pulling it off course. Using only orbital deviation data and classical mechanics, he calculated the mass, position, and trajectory of a body no telescope had ever found. On the night of 23 September 1846, Johann Gottfried Galle and Heinrich d'Arrest at the Berlin Observatory pointed their telescope at the coordinates Le Verrier had derived. Neptune was there — within one degree of the predicted position, found within an hour of beginning the search. British mathematician John Couch Adams had independently reached the same conclusion by the same method.
The detection model underlying adaptivePRO operates on the same premise: that meaningful departure from an established trajectory is observable before its cause becomes visible — and that rigorous analysis of deviation, not observation of outcome, is the basis for early identification.